Summit Therapeutics PLC Sponsored ADR Stock

$29.27

8.34% today

Nasdaq, Sep 16, 08:17 pm CET

ISIN

US86627R1023

Symbol

SMMT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Summit Therapeutics PLC Sponsored ADR Stock price

$31.93

+30.53 2,172.60% 5Y

Nasdaq, Closing price Fri, Sep 13 2024

+4.52 16.49%

ISIN

US86627R1023

Symbol

SMMT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$23.13b
Enterprise Value	$22.91b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	118.56
Revenue growth (TTM) Revenue growth	-100.00%
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-144.53m
Free Cash Flow (TTM) Free Cash Flow	$-96.67m
Cash position	$325.79m
EPS (TTM) EPS	$-0.23
P/E forward	negative
Short interest	17.22%

As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.

Get Started for Free Today

Summit Therapeutics PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

??

3 Analysts have issued a Summit Therapeutics PLC Sponsored ADR forecast:

3x Buy

100%

More details on Analyst Estimates Including Price Targets

3 Analysts have issued a Summit Therapeutics PLC Sponsored ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Summit Therapeutics PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter Annually

Assets

Jun '24
Current assets	329 329
Cash	326 326
Claims	0.95 0.95
Inventories	- -
Other current assets Other current assets Current assets	2.05 2.05

Fixed assets	13 13
Property, plant and equipment	8.94 8.94
Financial assets	- -
Intangible Assets	1.88 1.88
Other fixed assets Other assets Fixed assets	2.24 2.24


Total Assets	342 342

Liabilities

Jun '24
Equity	195 195

Debt capital	147 147
Current liabilities	140 140
Non-current liabilities	6.61 6.61


Total Capital	342 342

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Summit Therapeutics PLC Sponsored ADR Stock News

Positive

The Motley Fool

●

3 days ago

Why Summit Therapeutics Skyrocketed 123% This Week

Summit's Ivonescimab bested Keytruda in a phase 3 trial for lung cancer patients with the PD-L1 gene. Following the early-week stock spike, Summit raised over $200 million from investors.

Positive

The Motley Fool

●

4 days ago

Why Summit Therapeutics Stock Is Soaring Again Today

Several accredited investors entered an agreement to buy roughly $235 million of Summit Therapeutics stock. These investors included several of the biopharmaceutical company's executives and board members.

Positive

Investors Business Daily

●

4 days ago

Summit Therapeutics, With 85% Gain This Week, Rockets Again On $235 Million Sale

Summit Therapeutics stock rocketed again Thursday — adding onto an 85% gain this week — after raising $235 million in a private placement.

More Summit Therapeutics PLC Sponsored ADR News

Company Profile

Summit Therapeutics Plc operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company operates through the Drug Development segment, which covers its research and development activities carried out by the Group. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.

Head office	United Kingdom
CEO	Robert Zanganeh
Employees	105
Founded	2003
Website	www.smmttx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now